SecBot SecBot
PRESS-RELEASE ·Filed Apr 7, 2026

XENE

Xenon Pharmaceuticals Inc.
BEARISH
Impact 5/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and lack of revenue/guidance updates are negative signals; traders should monitor the AAN presentations for clinical data that could support future commercial potential of azetukalner, but near-term sentiment may remain pressured.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$57.65
T+0 close · Apr 7, 2026 · via day close
Latest settled
+5.74%
T+60 · $60.96
Vs SPY
−7.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $57.65entry
  2. T+1 · 7mo ago −0.19%α −2.73% · $57.54
  3. T+5 · 7mo ago +2.95%α −2.38% · $59.35
  4. T+20 · 7mo ago −0.43%α −10.21% · $57.40
  5. T+60 · 5mo ago +5.74%α −7.53% · $60.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% negative surprise. The company highlighted upcoming Phase 3 X-TOLE2 data presentations at AAN 2026, including long-term efficacy and safety data for azetukalner in focal onset seizures, but provided no revenue or guidance updates.

Key Financial Metrics

EPS
−$1.31
est −$1.20 · -9.2%
Revenue
$1.0M
est $1.0M · 0.0%
Rating
miss

Key Facts

  • Reported Q4 2025 EPS of -$1.31, missing consensus of -$1.20 by 9.4%
  • Reported revenue of $1.0M, in line with consensus
  • No revenue or earnings guidance was provided
  • Announced five abstracts at AAN 2026, including a Late-breaking Science oral presentation of Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures
  • Presented long-term 48-month data from X-TOLE open-label extension and real-world burden of titration in epilepsy

Financial Impact

EPS miss of 9.4% below expectations, no revenue growth or guidance provided

epsrevenue

Risk Factors

  • Clinical data from X-TOLE2 may not meet efficacy or safety expectations
  • Delayed or failed regulatory approval for azetukalner
  • Dilution risk from future capital raises given negative EPS and limited revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3269108

Track record

19 reports on XENE

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026